IL91298A - Peptides having bradykinin antagonist action, their preparation and use - Google Patents

Peptides having bradykinin antagonist action, their preparation and use

Info

Publication number
IL91298A
IL91298A IL9129889A IL9129889A IL91298A IL 91298 A IL91298 A IL 91298A IL 9129889 A IL9129889 A IL 9129889A IL 9129889 A IL9129889 A IL 9129889A IL 91298 A IL91298 A IL 91298A
Authority
IL
Israel
Prior art keywords
arg
pro
gly
tic
ser
Prior art date
Application number
IL9129889A
Other languages
Hebrew (he)
Other versions
IL91298A0 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IL91298A0 publication Critical patent/IL91298A0/en
Publication of IL91298A publication Critical patent/IL91298A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Peptides of the formula I A-B-C-E-F-K-(D)-Tic-G-M-F'-I (I> in which A is hydrogen, alkyl, alkanoyl, alkoxycarbonyl, alkylsulphonyl, cycloalkyl, aryl, arylsulphonyl, heteroaryl or an amino acid, each of which can optionally be substituted, B is a basic amino acid, C is a di- or tripeptide, E is the residue of an aromatic amino acid, F is, independently of one another, an amino acid which is optionally substituted in the side chain or is a direct bond, G is an amino acid, F' is defined as F, can be -NH-(CH2)2-8 or optionally a direct bond, I is -OH, -NH2 or -NHC2H5 and K is a radical -NH(CH2)-1-4-CO- or is a direct bond, have bradykinin-antagonistic action. Their therapeutic uses comprise all pathological states which are promoted, induced or sustained by bradykinin and bradykinin- related peptides. The peptides of the formula I are prepared by known methods of peptide synthesis.

Description

91298/2 PEPTIDES HAVING BRADYKININ ANTAGONIST ACTION, THEIR PREPARATION AND USE. .dm HOECHST AKTIENGESELLSCHAFT Description Peptides having bradykinin antagonist action The invention relates to novel peptides having bradykinin antagonist action and to a process for their preparation. Bradykinin antagonist peptides are described in Wo 86/07263 corresponding to IL 81477 in which, inter alia, L-Pro in position 7 of the peptide hormone bradykinin or other bradykinin analogs is replaced by a D-amino acid, such as D-Phe, D-Thi, D-Pal, CDF, D-Nal, MDY, D-Phg, D-His, D-Trp, D-Tyr, D-hPhe, D-Val, D-Ala, D-His, D-Ile, D-Leu and DOMT.
The invention is based on the object of finding novel active peptides having bradykinin antagonist action.
This object is achieved by the peptides of the formula I A-B-C-E-F-K- (D)-Tic-G-M-F'-I (Ii ' in which A ax) denotes hydrogen, (Ci-CeJ- lk l, ( Ci-Ce ) -alkanoyl , (Ci-Ce) -alkoxycarbonyl or (Cj-Ce) -alkylsulfonyl , in which in each case 1, 2 or 3 hydrogen atoms are optionally replaced by 1, 2 or 3 identical or different radicals from the series comprising carboxyl, amino, (Ci-CJ-alkyl, ( C^-C* ) -alkylamino , hydroxyl , (C1-CJ-alkoxy, halogen, di-tC1-C -alkylamino, carbamoyl , sulfamoyl, (Ci-C^ ) -alkoxycarbonyl , (C6-C12)-aryl and (C6-C12) -aryl- (Ci-Cs) -alkyl , or in which in each case 1 hydrogen atom is optionally replaced by a radical from the series comprising (C3-C8) -cycloalkyl, ( C1-C* ) -alkylsulfonyl , ( C1-C,, ) -alkylsulfinyl , ( C6-C12) -aryl- ( Ci-C^ ) -alkylsulfonyl , ( c6-ci2) -aryl- ( ^C^ ) -alkylsulfinyl , (C6-CX2)-aryloxy, (C3-C9) -heteroaryl and (C3-C9) -heteroaryloxy and 1 or 2 hydrogen atoms are replaced by 1 or 2 identical or different radicals from the series comprising carboxy1 , amino, ( Ci-C^, ) -alkylamino , hydroxyl , (Ci-CJ-alkoxy, halogen, di- (Ci-C* ) -alkylamino, carbamoyl, sulfamoyl, ( C^-C* ) -alkoxycarbonyl , (C6-C12)-aryl and ( C6-C12) -aryl- ( C^Cs) -alkyl , a2) denotes (C3-C8) -cycloalkyl, carbamoyl, which may be optionally substituted on the nitrogen by (Cj-Cg) -alkyl or (C6-C12)-aryl, (C6-C12)-aryl, (C7-C13 )-aryloyl, ( C6-C12) -arylsulfonyl , (C3-C9) -heteroaryl, or (C3-C9) -heteroaryloyl, where in the radicals defined under ax) and a2) in each case aryl, heteroaryl, aryloyl, arylsulfonyl and - - heteroaryloyl is optionally substituted by 1, 2, 3 or 4 identical or different radicals from the series comprising carboxyl, amino , nitro, ( Ci-C* ) -alky1amino , hydroxyl , (C^-C -alkyl, (Ci-CJ-alkoxy, halogen, cyano, di- ( C1-C* ) -alkylamino , carbamoyl, sulfamoyl and (Cj-CjJ-alkoxycarbonyl, or a3) denotes a radical of the formula II R1 - N - CH - C - (II) R2 RJ 0 R1 is defined as A under ax) or a2), R2 denotes hydrogen or methyl, R3 denotes hydrogen or (Ci-CgJ-alkyl, preferably (Ci-C -alkyl, which is optionally monosubstituted by amino, substituted amino, hydroxyl , carboxyl, carbamoyl , guanidino, substituted guanidino, ureido, mercapto, methylmercapto , phenyl , 4-chlorophenyl , 4-fluorophenyl , 4-nitrophenyl , 4-methoxyphenyl , 4-hydroxyphenyl , phthalimido, 4-imidazolyl , 3-indolyl , 2-thienyl , 3-thienyl , 2-pyr dyl, 3-pyridyl or cyclohexyl , where substituted amino stands for a compound -NH-A- and substituted guanidino stands for a compound -NH-C (NH) -NH-A, in which A is defined as under ax) or a2) ; B stands for a basic amino acid in the L- or D-con- figuration, which may be substituted in the side chain; C stands for a compound of the formula Ilia or Illb G'-G'-Gly G'- H-(CH2)n-CO (Ilia) (Illb) in which G' independently of one anotherdenotes a radical of the formula IV R4 R5 0 - N - CH - C - (IV) in which R* and R5 together with the atoms carrying them form a heterocyclic mono-, bi- or tricyclic ring system having 2 to 15 carbon atoms, and n is 2 to 8; E stands for the radical of an aromatic amino acid; F independently of one another denotes the radical of a neutral, acidic or basic, aliphatic or aromatic amino acid which may be substituted in the side chain, or stands for a direct bond; (D)-Tic denotes the radical of the formula V G is as defined above for G' or denotes a direct bond; F ' is as defined for F, denotes a radical -NH-(CH2)n-, with n = 2 to 8, or, if G does not denote a direct bond, can stand for a direct bond, and I is -OH, -NH2 or -NHC2H5, K denotes the radical -NH- (CH2)x-CO- with x = 1-4 or stands for a direct bond, and M is as defined for F, and their physiologically tolerable salts.
If not stated otherwise, the abbreviation of an amino acid radical without a stereodescriptor stands for the radical in the L-form (compare Schroder, Liibke, The · Peptides, Volume I, New York 1965, pages XXII-XXIII; Houben-Weyl, Methoden der Organischen Chemie (Methods of Organic Chemistry), Volume XV/1 and 2, Stuttgart 1974), such as, for example, Aad, Abu, TAbu, ABz, 2ABz, eAca, Ach, Acp, Adpd, Ahb, Aib, fJAib, Ala, flAla, AAla, Alg, All, A a, Amt, Ape, Apm, Apr, Arg, Asn, Asp, Asu, Aze, Azi, Bai, Bph, Can, Cit, Cys, Cyta, Daad, Dab, Dadd, Dap, Dapm, Dasu, D en, Dpa, Dtc, Fel, Gin, Glu, Gly, Guv, hAla, hArg, hCys, hGln, hGlu, His, hlle, hLeu, hLys, hMet, hPhe, hPro, hSer, hThr, hTrp, hTyr, Hyl, Hyp, 3Hyp, lie, Ise, Iva, Kyn, Lant, Lcn, Leu, Lsg, Lys, flLys, &Lys, Met, Mim, Min, nArg, Nle, Nva, Oly, Orn, Pan, Pec, Pen, Phe, Phg, Pic, Pro, Pro, Pse, Pya, Pyr, Pza, Qin, ROB, Sar, Sec, Sem, Ser, Thi, flThi, Thr, Thy, Thx, Tia, Tie, Tly, Trp, Trta, Tyr, Val .
Suitable radicals of a heterocyclic ring system of the formula IV are in particular radicals of heterocycles of the group below: Pyrrolidine (A) ; piperidine (B) ; tetrahydroisoquinoline (C) ; decahydroisoquinoline (D) ; octahydroindole (E) ; octahydrocyclopenta[b]pyrrole (F) ; 2-aza-bicyclo [2.2.2 ]- octane (G) ; 2-azabicyclo[2.2.1] heptane (H) ; 2-azaspiro- [4.5]decane (I.); 2-azaspiro[ 4.4 ]nonane (J); spiro[(bi- cyclo [2.2.1] heptane) -2, 3-pyrrolidine] (K) ; spiro[(bi-cyclo[2.2.2]octane)-2,3-pyrrolidine] (L) ; 2-azatricyclo-[4.3.0. l6,9]decane (M) ; decahydrocyclohepta[b]pyrrole (N) ; octahydroisoindole (0); octahydrocyclopenta[c]pyrrole (£) ; 2 , 3 , 3a, 4 , 5 , 7a-hexahydroindole (Q) ; tetrahydrothia-zole (R) ; 2-azabicyclo [ 3.1.0 ] hexane (S) ; isoxazolidine ( T ) pyrazolidine (U); hydroxyproline (V); all of which may be optionally substituted.
The heterocycles based on the abovementioned radicals are known, for example, from US-A-4 , 344 ,949, US-A-4 , 374 , 847 , US-A-4 , 350 , 704 , EP-A-50,800, EP-A-31,741, EP-A-51,020, EP-A-49,658, EP-A-49,605, EP-A-29,488, EP-A-46,953, EP-A-52,870, EP-A-271 , 865 , DE-A-3 , 226 , 768 , DE-A- 3 , 151 , 690 , DE-A-3,210,496, DE-A-3 , 211 , 397 , DE-A-3 , 211 , 676 , DE-A-3, 227, 055, DE-A-3 , 242 , 151 , DE-A-3 , 246 , 503 and DE-A-3,246,757.
Some of these heterocycles are furthermore proposed in DE-A-3, 818, 850.3.
If not stated otherwise in the individual case, alkyl can be straight-chain or branched. The same applies to radicals derived therefrom such as alkoxy, aralkyl or alkanoyl .
(C6-C12)-Aryl preferably denotes phenyl, naphthyl or biphenylyl. Radicals derived therefrom, such as aryloxy, aralkyl or aroyl, are to be formulated correspondingly.
Halo stands for fluorine, chlorine, bromine or iodine, preferably for chlorine.
Possible salts are, in particular, alkali metal or alkaline earth metal salts, salts with physiologically tolerable amines and salts with inorganic or organic acids such as, for example, HC1, HBr, H2S04, H3P04 maleic acid, fumaric acid, citric acid, tartaric acid and acetic acid.
Preferred peptides of the formula I are those in which B denotes Arg, Lys, Orn, 2 , 4-diaminobutyroyl or an L- homoarginine radical, where in each case the amino or guanidino group of the side chain may be substituted by A as described under a or a2); E stands for the radical of an aromatic amino acid in the L- or D-configuration , which contains 6 to 14 carbon atoms in the aryl moiety as ring members , such as phenylalanine which is optionally substituted by halogen in the 2-, 3- or 4-position, tyrosine, O-methyltyrosine, 2-thienylalanine, 2- pyridylalanine or naphthylalanine; F ' denotes the radical of a basic amino acid in the L- or D-configuration, such as Arg or Lys, where the guanidino group or amino group of the side chain may be replaced by A as described under ax) or a2) , or denotes a radical -NH-(CH2)n - with n = 2 to 8 and K stands for the radical -NH-(CH2)z-CO- with x = 2-4 or denotes a direct bond.
Particularly preferred peptides of the formula I are those in which B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain is unsubsti- tuted or may be substituted by (Ci-CaJ-alka oyl, (C7- Ci3) -aryloyl, (C3-C9) -heteroaryloyl, (Cj-CeJ-alkylsul- fonyl or (C6-C12) -arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted, as described under a2) , with 1, 2, 3 or 4 identical or different radicals .
E denotes phenylalanine, 2-chlorophenylalanine, 3-chlorophenylalanine , 4-chlorophenylalanine , 2-fluorophenylalanine, 3-fluorophenylalanine , 4-fluorophenylalanine, tyrosine, O-methyltyrosine or 0-(2-thienyl) alanine; K stands for a direct bond and M stands for a direct bond Very particularly preferred peptides of the formula I are those in which A denotes hydrogen, (D)- or (L)-H-Arg, (D)- or (L)-H- Lys or (D)- or (L)-H-Orn, B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain may be substituted by hydrogen, (Ci-CeJ-alkanoyl, (C7-C13)- aryloyl, (C3-C9) -heteroaryloyl , (C1-Ce)-alkylsulfonyl or (C6-C12) -arylsulfonyl , where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted with 1, 2, 3 or 4 identical or different radicals from the series comprising methyl, methoxy and halogen.
C denotes Pro-Pro-Gly, Hyp-Pro-Gly or Pro-Hyp-Gly E denotes Phe or Thia F denotes Ser, Hser, Lys, Leu, Val, Nle, lie or Thr K stands for a direct bond M stands for a direct bond G stands for the radical of a heterocyclic ring system of the formula IV, where the radicals of the hetero- cycles pyrrolidine (A) ; piperidine (B) ; tetrahydro- isoquinoline (C) ; cis- and trans-decahydroisoquino- line (D) ; cis-endo-octahydroindole (E) , cis-exo- octahydroindole (E), trans-octahydroindole (E), cis- endo-, cis-exo-, trans-octahydrocyclopentano[b]pyrrole, (F) or hydroxyproline (V) are preferred.
F' denote Arg and I stands for OH.
Examples of very particularly preferred peptides of the formula I are: H- (D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser- (D) -Tic-Oic- Arg- OH H- (D ) - Arg- Arg- Pro- Pro- Gly-Thia- Ser- (D)-Tic-Oic-Arg-OH H- (D)-Arg- Arg- Pro-Hyp- Gly- Phe-Ser- (D)-Tic-Oic-Arg-OH H- The peptides of the present invention were prepared by generally known methods of peptide chemistry, see, for example, Houben-Weyl, ethoden der organischen Chemie (Methods of Organic Chemistry), Volume 15/2, preferably by means of solid phase synthesis such as described, for example, by B. Merrifield, J.Am. Chem. Soc . 85., 2149 (1963) or R. C. Sheppard, Int. J. Peptide Protein Res. 21, 118 (1983) or by equivalent known methods. Urethane protective groups such as, for example, the tert-butyloxy-carbonyl ( Boc ) or fluorenylmethoxycarbonyl (Fmoc) protective group are used as o-amino protective group. If necessary for the prevention of side reactions or for the synthesis of specific peptides, the functional groups in the side chain of amino acids are additionally protected by suitable protective groups (see, for example, T.W. Greene, "Protective Groups in Organic Synthesis"), where primarily, Arg(Tos), Arg(Mts), Arg(Mtr), Arg(PMC), Asp(OBzl), Asp(OBut), Cys(4-MeBzl) , Cys(Acm), Cys(SBut), Glu(OBzl), Glu(OBut), His(Tos), His(Fmoc), His(Dnp), His(Trt), Lys(Cl-Z), Lys(Boc), Met(O), Ser(Bzl), Ser(But), Thr-(Bzl), Thr(But), Trp(Mts), Trp(CHO) , Tyr(Br-Z), Tyr(Bzl) or Tyr(But) are employed.
Solid phase synthesis begins at the C-terminal end of the peptide with the coupling of a protected amino acid to an appropriate resin. Starting materials of this type may be obtained by linking a protected amino acid via an ester or amide bond to a polystyrene or polyacrylamide resin modified with a chloromethyl, hydroxymethyl, benzhydryl-amino(BHA) or methylbenzhydrylamino (MBHA) group. The resins used as support materials are commercially obtainable. BHA and MBHA resins are usually used if the peptide synthesized is intended to have a free amide group at the C-terminus. If the peptide is intended to have a secondary amide group at the C-terminal end, a chloromethyl or hydroxymethyl resin is used and the splitting off is carried out using the corresponding amines. If it is wished to obtain, for example, the ethylamide, the peptide can be split off from the resin using ethylamine, the splitting off of the side chain protective groups subsequently being carried out by means of other suitable reagents. If it is intended to retain the tert-butyl protective groups of the amino acid side chain in the peptide, the synthesis is carried out using the Fmoc protective group for temporary blocking of the a-amino group of the amino acid using the method described, for example, in R.C. Sheppard, J.Chem.Soc, Chem.Comm 1982. 587, the guanidino function of the arginine being protected by protonation with pyridinium perchlorate and the protection of the other functionalized amino acids in the side chain being carried out using benzyl protective groups which can be split off by means of catalytic transfer hydrogenation (A. Felix et al. J. Org. Chem. 13. 4194 (1978) or by means of sodium in liquid ammonia (W. Roberts, J .Am . Chem . Soc . 76., 6203 (1954)).
After splitting off the amino protective group of the amino acid coupled to the resin using a suitable reagent, such as, for example, trifluoroacetic acid in methylene chloride in the case of the Boc protective group or a 20% strength solution of piperidine in dimethylformamide in the case of the Fmoc protective group, the subsequently protected amino acids are successively coupled in the desired sequence. The intermediately resulting N-terminal protected peptide resins are deblocked by means of the reagents described above before linkage with the subsequent amino acid derivative.
All possible activating reagents used in peptide synthesis can be used as coupling reagents, see, for ex-ample, Houben-Weyl, Methoden der organischen Chemie (Methods of Organic Chemistry), Volume 15/2, in particular, however, carbodiimides such as, for example, , ' -dicyclohexylcarbodiimide , N, ' -diisopropyl-carbodi-imide or N-ethyl-N ' - ( 3-dimethylaminopropyl ) -carbodiimide . The coupling can in this case be carried out directly by addition of amino acid derivative and the activating reagent and, if desired, a racemization-suppressing additive such as, for example, 1-hydroxy-benzotriazole (HOBt) (W. Konig, R. Geiger, Chem. Ber. 103. 708 (1970)) or 3-hydroxy-4-oxo-3,4-dihydrobenzo-triazine (HOObt) (W. Konig, R. Geiger, Chem. Ber. 103. 2054 (1970)) to the resin or, however, the preactivation of the amino acid derivative as symmetrical anhydride or HOBt or HOObt ester can be carried out separately and the solution of the activated species in a suitable solvent can be added to the peptide resin capable of coupling.
The coupling or activation of the amino acid derivative with one of the abovementioned activating reagents can be carried out in dimethylformamide, N-methylpyrrolidone or methylene chloride or a mixture of the solvents mentioned. The activated amino acid derivative is customarily employed in a 1.5 to 4 fold excess. In cases in which an incomplete coupling takes place, the coupling reaction is repeated without previously carrying out the deblocking of the a-amino group of the peptide resin necessary for the coupling of the following amino acid.
The successful course of the coupling reaction can be monitored by means of the ninhydrin reaction, such as described, for example, by E. Kaiser et al. Anal. Biochem. 34 595 (1970). The synthesis can also be auto-mated, for example using a peptide synthesizer model 430A from Applied Biosystems, it being possible either to use the synthesis program provided by the apparatus manufacturer or else, however, one set up by the user himself. The latter are in particular employed in the use of amino acid derivatives protected with the Fmoc group.
After synthesis of the peptides in the previously described manner, the peptide can be split off from the resin using reagents, such as, for example, liquid hydrogen fluoride (preferably in the peptides prepared according to the Boc method) or trifluoroacetic acid (preferably in the peptides synthesized according to the Fmoc method) . These reagents not only cleave the peptide from the resin but also the other side chain protective groups of the amino acid derivative. In this manner, the peptide is obtained in the form of the free acid in addition using BHA and MBHA resins. With the BHA or MBHA resins, the peptide is obtained as acid amide when splitting off is carried out using hydrogen fluoride or trifluoromethanesulfonic acid. Additional processes for the preparation of peptide amides are described in German Patent Applications P 37 11 866.8 and P 37 43 620.1. The splitting off of the peptide amides from the resin here is carried out by treatment with medium strength acids (for example trifluoroacetic acid) usually used in peptide synthesis, cation entrainer substances such as phenol, cresol, thiocresol, anisole, thioanisole, ethane-dithiol, dimethyl sulfide, ethyl methyl sulfide or similar cation entrainers customary in solid phase synthesis being added individually or as a mixture of two or more of these auxiliaries. In this case, the tri-fluoroacetic acid can also be used diluted by suitable solvents, such as, for example, methylene chloride.
If the tert-butyl or benzyl side chain protective groups of the peptides are to be retained, the splitting off of the peptide synthesized on a particularly modified support resin is carried out using 1% trifluoroacetic acid in methylene chloride, such as described, for example, in R.C. Sheppard J.Chem. Soc, Chem. Comm. 1982 , 587. If individual tert-butyl or benzyl side chain protective groups are to be retained, a suitable combination of synthesis and splitting off methods is used.
For the synthesis of peptides having a C-terminal amide grouping or an ω-amino or ω-guanidinoalkyl grouping, the modified support resin described by Sheppard is likewise used. After the synthesis, the peptide fully protected in the side chain is split off from the resin and subsequently reacted with the appropriate amine or ω-amino-alkylamine or ω-guanidinoalkylamine in classical solution synthesis, it being possible for optionally present additional functional groups to be temporarily protected in a known manner.
An additional process for the preparation of peptides having an ω-aminoalkyl grouping is described in German Patent Application P 36 35 670.0.
The peptides of the present invention were preferably synthesized by two general protective group tactics using the solid phase technique: The synthesis was carried out using an automatic peptide synthesizer model 430 A from Applied Biosystems, with Boc or Fmoc protective groups for temporary blockage of r.ne -amino group.
When using the Boc protective group, the synthesis cycles pre-programmed by the manufacturer of the apparatus were used for the synthesis.
The synthesis of the peptides having a free carboxyl group on the C-terminal end was carried out on a 4-( hydroxymethyl ) phenylacetamidomethylpolystyrene resin functionalized with the corresponding Boc amino acid (R.B. Merrifield, J. Org. Chem. 43, 2845 (1978)) from Applied Biosystems. An MBHA resin from the same firm was used for the preparation of the peptide amides.
N, ' -Dicyclohexylcarbodiimide or N, N ' -diisopropylcarbodi-imide were used as activating reagents . Activation was carried out as the symmetrical anhydride, as the HOBt ester or HOObt ester in CH2C12, CH2C12 - D F mixtures or NMP. 2-4 equivalents of activated amino acid derivative were employed for the coupling. In cases in which the coupling took place incompletely, the reaction was repeated .
During the use of the Fmoc protective group for the temporary protection of the a-amino group, our own synthesis programs were used for synthesis using the automatic peptide synthesizer model 43OA from Applied Biosystems. The synthesis was carried out on a p-ben-zyloxybenzyl alcohol resin (S. Wang, J.Am. Chem. Soc . 95, 1328 (1973)) from Bachem which was esterified by a known method (E. Atherton et al. J.C.S. Chem. Comm. 1981 , 336) using the appropriate amino acid. The activation of the amino acid derivatives as HOBt or HOObt esters was carried out directly in the amino acid cartridges provided by the apparatus manufacturer by addition of a solution of diisopropylcarbodiimide in DMF to the previously weighed-in mixture of amino acid derivative and HOBt or HOObt. Fmoc-amino acid-OObt esters prepared in substance can likewise be employed as described in European Patent Application 87,107,634.5. The splitting off of the Fmoc protective group was carried out using a 20% strength solution of piperidine in DMF in the reaction vessel. The excess of reactive amino acid derivative used was 1.5 to 2.5 equivalents. If the coupling was not complete, it was repeated as in the Boc method .
The peptides according to the invention have, individually or in combination, a bradykinin antagonist action which can be tested in various models (see Handbook of Exp. Pharmacol. Vol. 25, Springer Verlag, 1970, p. 53-55), for example on the isolated rat uterus, on the guinea pig ileum or on the isolated pulmonary artery of the guinea pig.
For testing the peptides according to the invention on the isolated arteria pulmonalis, guinea pigs (Dunkin Hartley) having a weight of 400 - 450 g are sacrificed by a blow to the back of the neck.
The thorax is opened and the arteria pulmonalis is carefully dissected out. The surrounding tissue is carefully removed and the arteria pulmonalis is cut spirally at an angle of 45°.
The vessel strip of 2.5 cm length and 3-4 mm width is fixed in a 10 ml capacity organ bath which is filled with Ringer solution.
Composition of the solution in mmol/1 NaCl 154 KC1 5.6 CaCl2 1.9 NaHC03 2.
Glucose 5.0 95% 02 and 5% C02 is bubbled through the solution, which is warmed to 37°C. The pH is 7.4 and the preload on the vessel strip is 1.0 g.
The isotonic contraction changes are detected using a lever arrangement and an HF modem (position sensor) from Hugo Sachs and recorded on a compensating recorder (BEC, Goerz Metrawatt SE 460).
After equilibration for 1 hour, the experiment is begun. After the vessel strips have achieved their maximum sensitivity to 2 x 10"7 mol/1 of bradykinin - bradykinin leads to a contraction of the vessel strips - the peptides are allowed to act for 10 minutes in each case in the doses 5 x 10"8 - 1 x 10"5 mol/1 and, after adding bradykinin again, the decrease in the effect of bradykinin as opposed to the control is compared.
For the detection of a partial agonistic effect, the peptides are used in the doses 1 x 10"5 - 1 x 10"3 mol/1.
The IC50 values of the peptides according to the invention calculated from the dose-effect curves are shown in Table 1.
Table It Compound IC50 [M] H-(D). ■Arg-Arg-Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH 4,6 10" 6 H-(D). ■Arg-•Arg- Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Thia-Arg-OH 2,1 10" 6 H-(D). ■Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Phe-Arg-OH 1.2 10- 5 H-(D). •Arg-Arg-Hyp-Pro-Gly-Phe-Glo-(D)-Tic-Phe-Arg-OH 2,4 10' 5 H-(D). ■Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Pe-Arg(Mtr)-OH 2,5 10" 5 H-(D). ■Arg-Arg- Hyp-Pro-Gly-Phe-Ser-(D)-Tic-Pro-Arg-OH 2,5 10-7 H-(D). -Arg- Arg- Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Pro-Arg-OH 1,9 ■ 10" 7 H-(D)-■Arg-Arg- Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH 5,6 10-8 H-(0)-■Arg-Arg-Hyp-Pro-Gly-Thia-Ser-e-Ala-(D)-Tic-Aoc-Arg-OH 1,7 · 10' 6 H-(D). ■Arg- Arg- Hyp-Pro-G1y-Thia-Ser-Gly-(D)-Tic-Aoc-Arg-0H 3,9 10-7 H-(D). ■Arg-■Arg- Hyp-Pro-Gly-Thia-G1y-(D)-Tic-(D,L)-0ic-Arg-0H 3,2 10" 7 H-(D). -Arg-•(D)-Arg-Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH 4,8 10-7 H-(D) -Arg-■Arg- Hyp-Pro-Gly-Thia-Ser-(D)-Tic-Tic-Arg-OH 1.7 10" 7 Compound IC50 [M] H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Aoc-Arg-OH 1,1 • 10- 8 H-(D)-Arg-Arg-Pro-Hyp-G1y-Phe-Ser-(D)-Tic-Aoc-Arg-0H 4,6 • 10" 8 H-(D)-Tyr-Arg-Pro-Hyp-Gly-T ia-Ser-(D)-Tic-Aoc-Arg-OH 6,2 • 10" 8 H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-(D)-Oic-Arg-0H 2,6 • 10" 5 H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH 5,4 • 10" 9 H-(D)-Arg-Lys-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Aoc-Arg-OH 3,2 • 10" 7 H-(D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH 6,8 • 10' 9 H- (D)-Arg-Arg- (N02)-Pro-Hyp-Gly-Phe-Ser- (O)-Tic-Aoc-Arg-OH 6,4 • 10- 8 H-(D)-Arg-Arg-Pro-Pro-Gly-Thia-Ser-(D)-Tic-Oic-Arg-OH 4,2 • 10" 9 H-(D)-Arg-Pro-Hyp-Gly-Phe-Ser-(D)-Tic-Oic-Arg-OH 3,4 • 10- 7 H-Arg-(Tos)-Pro-Hyp-G1y-Phe-Ser-(D)-Tic-Dic-Arg-0H 3,0 • 10- 8 H-Arg-(Tos)-Pro-Hyp-Gly-T ia-Ser-(D)-Tic-Dic-Arg-OH 1.8 • 10" 8 The therapeutic utility of the peptides according to the invention includes all pathological states which are mediated, caused or supported by bradykinin and brady- kinin- related peptides. This includes, inter alia, traumas, such as wounds, burns, rashes, erythemas, edemas, angina, arthritis, asthma, allergies, rhinitis, shock, inflammations, low blood pressure, pain, itching and changed sperm motility.
The invention therefore also relates to the use of peptides of the formula I as medicaments, and to pharmaceutical preparations which contain these compounds .
Pharmaceutical preparations contain an effective amount of the active substance of the formula I - individually or in combination - together with an inorganic or organic pharmaceutically utilizable excipient.
Administration can be carried out enterally, parenterally - such as, for example, subcutaneous ly, i.m. or i.v. sublingually, epicutaneously, nasally, rectally, intra- vaginally, intrabuccally or by inhalation. The dosage of the active substance depends on the mammal species, the body weight, age and on the manner of administration.
The pharmaceutical preparations of the present invention are prepared in solution, mixing, granulating or tablet coating processes known per se.
For oral administration or application to the mucosa, the active compounds are mixed with the customary additives for this, such as excipients, stabilizers or inert diluents, and brought into suitable forms for administration, such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily suspensions or aqueous, alcoholic or oily solutions, by customary methods. Inert excipients which may be used are, for example, gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose, magnesium stearyl fumarate or starch, in particular maize starch. In this case, the preparation may be present both as dry and moist granules. Suitable oily excipients or solvents are, for example, vegetable or animal oils, such as sunflower oil and cod liver oil.
A preparation for topical application may be present as an aqueous or oily solution, lotion, emulsion or gel, ointment or fatty ointment or, if possible, in spray form, it being possible to improve the adhesion, if desired, by addition of a polymer.
For the intranasal form of administration, the compounds are mixed with the customary auxiliaries for this, such as stabilizers or inert diluents, and brought into suitable forms for administration, such as aqueous, alcoholic or oily suspensions or aqueous, alcoholic or oily solutions, by customary methods. Chelating agents, ethylenediamine-Ν,Ν,Ν' ,Ν'-tetraacetic acid, citric acid, tartaric acid or their salts may be added to aqueous intranasal preparations. Administration of the nasal solutions can be carried out by means of metered atomizers or as nasal drops, having a viscosity-increasing component, or nasal gels or nasal creams.
For administration by inhalation, atomizers or pressurized gas packs using inert carrier gases can be used.
For intravenous , subcutaneous , epicutaneous or intra-dermal administration, the active compounds or their physiologically tolerable salts, if desired with the pharmaceutically customary auxiliaries, for example for isotonisizing or adjusting pH, and solubilizers , emul-sifiers or other auxiliaries, are brought into solution, suspension or emulsion.
Because of the short half-lives of some of the medicaments described in body fluids, the use of injectable sustained release preparations is efficient. Medicament forms which may be used are, for example, oily crystal suspensions, microcapsules, rods or implants, it being possible to synthesize the latter from tissue-compatible polymers, in particular biodegradable polymers, such as, for example, those based on polylactic acid/ polyglycolic acid copolymers or human albumin.
A suitable dose range for forms for topical application and administration by inhalation are solutions containing 0.01-5 mg/ml, and with forms for systemic administration 0.01-10 mg/kg is suitable.
List of abbreviations: The abbreviations used for amino acids correspond to the three-letter code customary in peptide chemistry as described in Europ. J. Biochem. 138. 9 (1984). Additionally used abbreviations are listed below.
Acm Acetamidomethyl i-Ahx £-Aminohexanoyl Aoc cis, endo-2-Azabicyclo[3.3.0]octane-3-S carbonyl Boc tert-Butyloxycarbonyl But tert-Butyl Bzl Benzyl Cl-Z 4-Chlorobenzyloxycarbonyl DMF Dimethylformamide Dnp 2 ,4-Dinitrophenyl Fmoc 9-Fluorenylmethoxycarbonyl Me Methyl 4-Mebzl 4-Methylbenzy1 Mtr 4-Methoxy-2 , 3 , 6-trimethylphenylsulfonyl Mts Mesitylene-2-sulfonyl NMP N-Methylpyrrolidine Oic cis-endo-octahydroindol-2-ylcarbonyl Opr Isoxazolidin-3-ylcarbonyl Pmc 2,2,5,7, 8-Pentamethylchroman-6-sulfonyl TFA Trifluoroacetic acid Tcs 4-Methylphenylsulfony1 Thia 2-Thienylalanyl Tic 1,2,3 , 4-Tetrahydroisoquinolin-3-ylcarbonyl Trt Trityl The following examples are intended to illustrate the preferred methods for solid phase synthesis of the peptides according to the invention, without limiting the invention thereto.
The amino acid derivatives below were used: Fmoc- Arg(Mtr )-0H, Boc- {D)-Arg- OH, Fmoc-Arg(Pmc)-OH, Fmoc-Hyp-OH, Fmoc-Pro-OObt, Fmoc-Gly-OObt, Fmoc-Phe-OObt , Fmoc-Ser (tBu)-OObt, Fmoc- (D)-Tic- OH, Fmoc-Gln-OH, Fmoc-Aoc-OH, Fmoc-Thia-OH, Fmoc-Opr-OH, Fmoc- (D)-Asn-OH, Fmoc- fJ-Ala- OH, Fmoc-Oic-OH.
Example 1 : H- ( D) -Arg-Arg-Hyp-Pro-Gly-Phe-Ser- (D) -Tic-Phe-Arg-OH was synthesized stepwise using a peptide synthesizer model 430 A from Applied Biosystems by the Fmoc method on a p-benzyloxybenzyl alcohol resin from Novabiochem (loading about 0.5 mmol/g of resin) esterified with Fmoc-Arg(Mtr)-OH. 1 g of the resin was employed and the synthesis was carried out with the aid of a synthesis program modified for the Fmoc method.
In each case 1 mmol of the amino acid derivative having a free carboxyl group together with 0.95 mmol of HOObt was weighed into the cartridges of the synthesizer. The preactivation of these amino acids was carried out directly in the cartridges by dissolving in 4 ml of D F and adding 2 ml of a 0.55 mol solution of diisopropyl-carbodiimide in DMF.
The HOObt esters of the other amino acids were dissolved in 6 ml of NMP and then similarly coupled to the resin previously deblocked using 20% piperidine in DMF, like the amino acids preactivated in situ. After completion of the synthesis, the peptide was split off from the resin using thioanisole and ethanedithiol as cation entrainers, with simultaneous removal of the side chain protective groups using trifluoroacetic acid. The residue obtained after stripping off the trifluoroacetic acid was repeatedly digested with ethyl acetate and centrifuged. The residue which remained was chromatographed on ®Sephadex LH 20 using 10% strength acetic acid. The fractions containing the pure peptide were combined and freeze-dried.
MS (FAB) : 1294 (M+H) The peptides of Examples 2 to 24 below were prepared and purified analogously to Example 1.
Example 2: H- (D)-Arg-Arg-Hyp-Pro-Gly-Phe- (D)-Ser- (D)-Tic-Phe-Arg-OH MS (FAB) : 1294 (M+H) Example 3: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Thia-Arg-OH MS (FAB) : 1306 (M+H) Example 4 : H- (D)-Arg-Arg-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Phe- Arg-OH MS (FAB) : 1294 (M+H) Example 5: H- (D)-Arg-Arg-Hyp-Pro-Gly-Phe-Gln- (D)- Tic- Phe-Arg-OH MS (FAB) : 1335 (M+H) Example 6 : H- (D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser- (D)-Tic-Pro- Arg-OH MS (FAB) : 1244 (M+H) Example 7: H- (D)-Arg-Arg-Hyp-Pro-Gly-Phe-Trp- (D)-Tic-Phe-Arg-OH MS (FAB) : 1393 (M+H) Example 8: H- (D) -Arg-Arg-Hyp- Pro- Gly-Thia- Ser- (D)-Tic- Pro-Arg-OH MS (FAB) : 1250 (M+H) Example 9: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia- (D)-Asn- (D)-Tic-Thia-Arg-OH MS (FAB) : 1333 (M+H) Example 10 : H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Opr- (D)-Tic-Thia-Arg-OH MS (FAB ) : 1301 (M+H) Example 11: H- (D)- Arg- Arg- Hyp- Pro- Gly-Thia- (D)-Gln- (D)-Tic-Thia-Arg-OH MS (FAB) : 1347 (M+H) Example 12: H- (D) -Arg-Arg-Hyp- Pro- Gly-Thia- Ser- Gly- (D)-Tic-Pro-Arg-OH MS (FAB) : 1307 (M+H) Example 13: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Pro-Phe-OH MS (FAB) : 1241 (M+H) Example 14 : H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Pro-Phe-Arg-OH MS (FAB) : 1397 (M+H) Example 15: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-B-Ala- (D ) - Tic- Pro- Arg- OH MS (FAB) : 1321 (M+H) Example 16: H- (D)- Arg- Arg- Hyp- Pro- Gly- hia- Gly- (D)-Tic-Pro-Arg-OH MS (FAB) : 1220 (M+H) Example 17: H- (D)-Arg-Arg-Aoc-Pro-Gly-Thia-Ser- (D)-Tic-Thia-Arg-OH MS (FAB) : 1330 (M+H) Example 18: H- (D)-Arg-Arg-Pro-Aoc-Gly-Thia-Ser- (D)-Tic- Thia-Arg- OH MS (FAB) : 1330 (M+H) Example 19: H- (D) -Arg- Arg-Hyp- Pro- Gly- Thia- Ser- (D) - Tic-Aoc-Arg- OH MS (FAB) : 1290 (M+H) Example 20: H- (D)-Arg-Arg-Opr-Pro-Cly-Thia-Ser- (D)- ic-Pro-Arg- OH MS (FAB) : 1236 (M+H) Example 21: H- (D)-Arg-Arg-Pro-Opr-Gly-Thia-Ser- (D)- Tic-Pro-Arg- OH MS (FAB) : 1236 (M+H) H- ^rg2-^ MS (FAB) : 1252 (M+H) Example 23: H- (D)-Arg- (D) - Arg-Hyp- ro-Gly-Thia- Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1290 (M+H) Example 24 : H- (D) - Arg- Arg- Pro-Hyp- Gly- Thia- Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1290 (M+H) Examples 25 - 27: H- ( D ) -Arg-Arg ( Mtr ) -Pro-Hyp-Gly-Phe-Ser- ( D) -Tic-Phe-Arg- OH and H-(D) -Arg-Arg-Pro-Hyp-Gly-Phe-Ser- ( D) -Tic-Phe-Arg (Mtr) - OH and H-(D) -Arg-Arg (Mtr) -Pro-Hyp-Gly-Phe-Ser- (D) -Tic-Phe-Arg(Mtr) -OH are prepared analogously to Example 1, the splitting off of the side chain protective groups and the peptide from the resin by means of trifluoroacetic acid being limited to 30 minutes at room temperature. Under the conditions thus selected, only a negligible splitting off of the Mtr protective group on the arginine takes place. The partially deblocked peptides are separated by chromatography on reverse phase material and purified. 25: H- (D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Phe- Arg- OH MS (FAB): 1506 (M+H) 26: H- (D)-Arg-Arg(Mtr)-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Phe- Arg(Mtr)-0H MS (FAB): 1718 (M+H) 27: H- (D)- Arg- Arg-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Phe-Arg(Mtr)- OH MS (FAB): 1506 (M+H) The peptides of Examples 28 - 31 below were prepared and purified analogously to Examples 25 - 27.
Example 28: H- (D)-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Pro-Arg-OH MS (FAB) : 1462 (M+H) Example 29: H- (D) - Arg-Arg- Hyp- Pro- Gly- Thia- Ser- (D)-Tic-Pro-Arg(Mtr ) -OH MS (FAB) : 1462 (M+H) Example 30: H- (D ) -Arg- Arg (Mtr ) -Hyp-Pro- Gly- Thia- Ser- (D)-Tic-Pro-Phe-OH MS (FAB) : 1453 (M+H) Example 31: H- (D)-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1502 (M+H) Example 32: H-Arg-Hyp-Pro-Gly-Phe-Ser- ( D) -Tic-Phe-NH- (CH2) *-NH2.
The peptide synthesis was carried out on 1 g of an amino-methyl resin which was modified with an attachment group of the type described in EP-A 264,802, using Fmoc-amino acid-OObt esters with an automatic peptide synthesizer (model 430A from Applied Biosystems) and synthesis programs which have themselves been modified. To this end, in each case 1 mmol of the appropriate amino acid derivative was weighed into the cartridges provided by the manufacturer, and Fmoc-Arg(Mtr) -OH, Fmoc-Hyp-OH and Fmoc-(D)-Tic-OH were weighed into the cartridges together with 0.95 mmol of HOObt. The preactivation of these amino acids in situ was carried out directly in the cartridges by dissolving in 4 ml of DMF and adding 2 ml of a 0.55 M solution of diisopropylcarbodiimide in DMF. The HOObt esters of the other amino acids were dissolved in 6 ml of NMP and then coupled to the resin previously deblocked using 20% piperidine in DMF, like the amino acids preactivated in situ, the amino acids activated in situ being doubly coupled. After completion of synthesis, the peptide 4- aminobutylamide was split off from the resin with simultaneous removal of the side chain protective groups with trifluoroacetic acid which contained thioanisole and Tricresol as cation entrainers . The residue obtained after stripping off the trifluoroacetic acid was repeatedly digested with ethyl acetate and centrifuged. The crude peptide which remained was chromatographed on ®Sephadex G25 using IN acetic acid. The fractions containing the pure peptide were combined and freeze-dried .
The compounds of Examples 33 - 35 were prepared analogously to Example 32: Example 33: H-D-Arg-Arg-Hyp-Pro-Gly-Phe-Ser- (D)-Tic-Phe-NH- (CH2)4-NH2 MS(FAB) : 1208(M+H) Example 34: HOOC- (CH2)2-CO-Arg-Hyp-Pro-Gly-Phe-Ser- (D)-Tic-Phe-NH- (CH2)4-NH2 MS(FAB):1152(M+H) Example 35: HOOC- (CH2)2-CO- (D)-Arg-Hyp-Pro-Gly-Bhe-Ser- (D)-Tic-Phe-NH- (CH2)4-NH2 MS(FAB):1308(M+H) The examples 36 to 161 were synthesized according to the method described under Example 1.
Example 36: H- (O-Arg-Ars-Hyp-Pro-Gly-Thia-Ser-G-y- (Dl-Tic-Pro-Arg-OH MS (FAB) : 1307 (M+H) Example 37: H- (D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-Gly- (D)-Tic-Pro- Arg-OH MS (FAB) : 1307 (M+H) Example 38: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- (D)-Tic-Pro-Phe-OH MS (FAB) : 1241 (M+H) Example 39: H-{D)-Arg.Arg-Hyp-Pro-Gly.Thia-Ser-e-Ala-(D)-Tic-Aoc-Arg MS (FAB) : 1361 (M+H) Example 40: H-(D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-fi-Ala-(D)-Tic-Aoc-Arg-OH MS ( FAB ) : 1361 (M+H) Example 41: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Ser- ( )- Tic-Pro-Phe- Arg-OH MS {FAB ) : 1397 (M+H) Example 42: H- (D)-Arg-Arg-Pro-Hyp-Gly-T ia-Ser- (D)-Tic-Pro-Phe-Arg- OH MS (FAB) : 1397 (M+H) Example 43: H- (D)-Arg-Arg-Pro-Hyp-Gly-Thia-Gly- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1260 (M+H) Example 44: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-Gly- (D)-Tic-Aoc-Arg-OH MS ( FAB ) : 1260 (M+H) Example 45: H- (D)-Arg- (D)-Arg-Hyp-Pro-Gly-Thia-Ser- (D)- Tic-Aoc-Arg- OH MS (FAB) : 1290 (M+H) Example 46: H- (D)-Arg- (D)-Arg-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1290 (M+H) Example 47: H- (D ) - Arg- Arg-Hyp-Pro- Gly- Thia- Ser- (D) -Tic-Tic-Arg- OH MS (FAB) : 1312 (M+H) Example 48: H- (D)-Arg-Arg-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Tic-Arg-OH MS (FAB) : 1312 (M+H) Example 49 : H- (D)- Arg- Arg-Pro-Pro-Gly-Thia-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1274 (M+H) Example 50: H- (D)-Arg-Arg-Hyp-Pro-Gly-T ia- (D)-Tic- Aoc-Arg-OH MS (FAB) : 1203 (M+H) Example 51: H- (D)-Arg-Arg-HyP-Pro-Gly-Aoc-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1274 (M+H) Example 52: H- (D)-Arg-Arg-Hyp-Pro-Gly-Thia-U-Ala- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1274 (M+H) Example 53: H- (D) -Arg-Arg- Pro-Hyp-Gly-Thia- β- Ala- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1274 (M+H) Example 54: H- (D)-Arg-Arg-Hyp-Pro-Gly-Asp-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1252 (M+H) Example 55: H- (D)-Arg-Arg-Pro-Hyp-Gly-Asp-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1252 (M+H) Example 56 : H- (D)-Arg-Arg-Hyp-Pro-Gly-Trp-Ser- (P)-Tic-Aoc-Arg-OH MS (FAB) : 1323,7 (M+H) Example 57: H- (D)-Tyr-Arg-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB ) : 1297,7 (M+H) Example 58: H- (D) -Arg-Arg- Pro-Hyp-Gly-Thia- Ser- (D)-Tic- (D)-Oic-Arg-OH MS ( FAB ) : 1304,6 (M+H) Example 59: H-(D)-Arg-Arg-Pro.Hyp.Gly.T ia-Ser-(D)-Tic-Oic.Arg-OH MS ( FAB ) : 1304,6 (M+H) Example 60: H- (D) - Arg- Arg-Pro-Pro-Gly-Thia- Ser- (D)-Tic-Oic-Arg-OH MS (FAB) : 1289 (M+H) Example 61: H- (D)-Arg-Lys-Pro-Hyp-Gly-Thia-Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1262 (M+H) Example 62: H- (D) - Arg-Lys-Pro-Hyp-Gly-Thia- Ser- (D)-Tic-Oic-Arg-OH MS (FAB) : 1276 (M+H) Example 63: H- (D) -Arg- Lys-Pro- Pro- Gly-Thia- Ser- (D)-Tic-Oic-Arg- OH MS (FAB) : 1260 (M+H) Example 64: H- (D ) - Arg- Arg- Pro-Hyp- Gly- Phe- Ser- (D ) -Tic- Oic-Arg- OH MS (FAB) : 1298 (M+H) Example 65: H- (D)-Arg-Arg-Hyp-Pro-Gly-Phe-Ser- (D)-Tic-Oic-Arg-OH MS (FAB) : 1298 (M+H) Example 66: H- (D)-Arg-Arg-Pro-Pro-Gly-Phe-Ser- (D)-Tic-Oic-Arg-OH MS (FAB) : 1282 (M+H) Example 67: H- (D )- Arg- Arg (N02)-Pro-Hyp- Gly- Phe- Ser- (D)-Tic-Aoc-Arg-OH MS (FAB) : 1329,7 (M+H) Example 68: H- (D)-Arg-Arg(N02)-Pro-Hyp-Gly-Phe-Ser- (D)-Tic-Oic-Arg-OH MS (FAB): 1343 (M+H) Example 69: H- (D)-Arg-Arg(N02)-Pro-Pro-Gly-Phe-Ser- (D)-Tic-Oic-Arg-OH MS (FAB) : 1327 (M+H) Example 70: H- {D)-Arg-Arg{N02)-Pro-Pro-Gly-Thia-Ser- (D) -Tic-Oic-Arg- OH MS (FAB ) : 1333 (M+H) Example 71: H- (D) -Arg- Arg (N02) -Pro-Hyp- Gly- Thia- Ser- (D)-Tic-Oic-Arg-OH MS ( FAB ) : 1349 (M+H) Example 72: H-Arg (Tos)- Pro-Hyp- Gly-Thia- Ser- D- Tic- Oic- Arg- OH MS (FAB) : 1302 (M+H) Example 73: H- Arg- ro-Hyp- Gly- Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1142 (M+H) Example 74: H-Lys ( - CO-NH- C6H5 ) - Pro-Hyp- Gly- Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1233 (M+H) Example 75: H-Arg (Tos ) - Pro-Hyp- Gly- Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1296 (M+H) Example 76: H- Lys (Nicotinoyl ) - Pro- Hyp- Gly-Phe- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1219 (M+H) Example 77: H- Arg (Tos ) - Pro-Hyp- Gly-Phe- Ser-D-Tic-Aoc-Arg- OH MS (FAB) : 1282 (M+H) Example 78: Ac- Arg (Tos ) - Pro-Hyp- Gly- Phe- Ser-D-Tic- Aoc-Arg- OH MS (FAB) : 1324 (M+H) Example 79: H- D- Arg- Arg (Tos ) - Pro- Hyp- Gly- Phe- Ser- D-Tic- Aoc- Arg- OH MS (FAB ) : 1438 (M+H) Example 80: H- Arg ( Tos ) -Hyp- Pro- Gly- Thia- Ser-D- Tic- Oic-Arg- OH MS (FAB ) : 1302 (M+H) Example 81: H-Arg- Hyp- Pro- Gly-Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1142 (M+H) Example 82: H-Lys ( - CO-NH- C6H5) -Hyp-Pro-Gly- Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1233 (M+H) Example 83: H-Arg ( os ) -Hyp- Pro- Gly-Phe- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1296 (M+H) Example 84: H-Lys (Nicotinoy1 ) -Hyp- Pro- Gly-Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1219 (M+H) Example 85: H- Arg (Tos ) -Hyp-Pro- Gly- Phe- Ser- D- Tic- Aoc- Arg- OH MS (FAB ) : 1282 (M+H) Example 86: Ac- Arg (Tos) -Hyp- Pro- Gly- Phe- Ser-D- Tic- Aoc-Arg- OH MS ( FAB ) : 1324 (M+H) Example 87: H- D-Arg- Arg (Tos ) -Hyp- Pro- Gly- Phe- Ser-D- Tic-Aoc-Arg- OH MS (FAB) : 1438 (M+H) Example 88: H-Arg (Tos )- Pro- Pro- Gly-Thia- Ser- D- Tic- Oic- Arg- OH MS (FAB) : 1286 (M+H) Example 89: H- Arg- Pro- Pro- Gly- Phe- Ser- D- Tic- Oic-Arg- OH MS (FAB) : 1126 (M+H) Example 90: H-Lys ( - CO-NH- C6H5 ) -Pro-Pro- Gly- Phe- Ser-D-Tic- Oic- Arg- OH MS (FAB) : 1217 (M+H) Example 91: H-Arg (Tos ) - Pro- Pro- Gly-Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1280 (M+H) Example 92: H-Lys (Nicotinoyl ) - Pro- Pro- Gly- Phe- Ser-D- Tic- Oic-Arg-OH MS (FAB) : 1203 (M+H) Example 93: H-Arg (Tos) -Pro-Pro- Gly- Phe- Ser-D-Tic-Aoc-Arg- OH MS (FAB) : 1266 (M+H) Example 94: Ac- Arg (Tos ) - Pro-Pro- Gly-Phe- Ser- - ic-Aoc-Arg- OH MS (FAB) : 1308 (M+H) Example 95: H-D- Arg-Arg(Tos ) - Pro- Pro- Gly-Phe- Ser-D-Tic-Aoc-Arg- OH MS (FAB) : 1422 (M+H) Example 96: H- Arg- Pro-Hyp- Gly- Thia- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1148 (M+H) Example 97: H- Lys ( - CO-NH- C6H5 ) -Pro-Hyp- Gly- hia- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1239 (M+H) Example 98: H- Lys (Nico inoyl ) - Pro-Hyp- Gly- Thia- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1225 (M+H) Example 99: H-Arg (Tos) -Pro-Hyp- Gly- Thia- Ser-D-Tic-Aoc- Arg- OH MS (FAB ) : 1288 (M+H) Example 100: Ac- Arg (Tos ) - Pro- Hyp- Gly- Thia- Ser- D- Tic-Aoc-Arg- OH MS (FAB) : 1330 (M+H) Example 101: H-D-Arg-Arg (Tos ) -Pro-Hyp- Gly-Thia- Ser-D-Tic-Aoc-Arg- OH MS (FAB) : 1444 (M+H) Example 102: H- Arg-Hyp- Pro- Gly-Thia- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1148 (M+H) Example 103: H-Lys(- CO-NH-CgHg)-Hyp-Pro- Gly-Thia- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1239 (M+H) Example 104: H- Lys (Nicotinoyl ) - Hyp- Pro- Gly-Thia- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1225 (M+H) Example 105: H- Arg (Tos ) - Hyp-Pro- Gly- Thia- Ser-D-Tic-Aoc-Arg- OH MS (FAB) : 1288 (M+H) Example 106: Ac- Arg ( Tos ) -Hyp- Pro- Gly- Thia- Ser-D- Tic- Aoc-Arg- OH MS (FAB) : 1330 (M+H) Example 107: H-D- Arg- Arg (Tos) -Hyp-Pro- Gly-Thia- Ser-D- Tic-Aoc-Arg- OH MS (FAB) : 1440 (M+H) Example 108: H- Lys ( - CO- NH- C6H5 ) - Pro- Pro- Gly- Thia- Ser- D- Tic- Oic-Arg- OH MS (FAB) : 1225 (M+H) Example 109: H- Lys (Nicotinoyl ) - Pro- Pro- Gly-Thia- Ser-D- Tic- Oic-Arg- OH MS ( FAB ) : 1209 (M+H) Example 110: H- Arg (Tos ) - Pro- Pro- Gly- hia- Ser- D- Tic-Aoc-Arg- OH MS (FAB): 1272 (M+H) Example 111: Ac-Arg (Tos) -Pro-Pro- Gly- hia- Ser-D- ic-Aoc-Arg- OH MS (FAB) : 1314 (M+H) Example 112: H-D-Arg- Arg (Tos ) - Pro-Pro- Gly- Thia- Ser- -Tic-Aoc-Arg- OH MS (FAB) : 1428 (M+H) Example 113: H-D-Arg- Lys (Nicotinoyl )-Pro- Pro- Gly-Thia- Ser-D- Tic- Oic-Arg-OH MS (FAB) : 1365 (M+H) Example 114: H-D-Arg- Lys (- CO-NH-C6H5 ) - Pro- Pro- Gly- Thia- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1379 (M+H) Example 115: H- D- Arg-Arg( Tos ) - Pro- Pro- Gly- Thia- Ser-D- Tic- Oic- Arg- OH MS (FAB) : 1442 (M+H) Example 116: H- Lys- Lys- (Nicotinoyl ) - Pro- Pro- Gly- hia- Ser-D-Tic- Oic-Arg-OH MS ( FAB ) : 1337 (M+H) Example 117 : H-Lys-Lys( -CO- H-C6H5)-Pro-Pro-Gly-Thia- Ser-D-Tic- Oic- Arg-OH MS ( FAB ) : 1351 (M+H) Example 118: H- Lys-Arg (Tos ) - Pro- Pro- Gly-Thia- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1414 (M+H) Example 119: H-D- Arg- Lys (Nicotinoyl )- Pro-Hyp- Gly- Thia- Ser-D-Tic- Oic-Arg-OH MS (FAB) : 1381 (M+H) Example 120: H- D- Arg-Lys- (CO-NH- C&H5 ) -Pro-Hyp- Gly-Thia- Ser-D- Tic- Oic-Arg- OH MS ( FAB ) : 1395 (M+H) Example 121: H-D-Arg-Arg (Tos ) -Pro-Hyp- Gly- Thia- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1458 (M+H) Example 122: H-Lys- Lys (- CO-NH- C6H5) -Pro-Hyp- Gly-Thia- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1367 (M+H) Example 123: H- Lys- Lys (Nicotinoyl ) -Pro-Hyp- Gly- Thia- Ser-D- Tic- Oic-Arg-OH MS (FAB) : 1353 (M+H) Example 124: H-Lys- Arg (Tos) -Pro-Hyp- Gly-Thia- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1430 (M+H) Example 125: H- D- Arg- Lys (Nicotinoyl ) - Pro- Pro- Gly-Phe- Ser-D- Tic- Oic-Arg- OH MS ( FAB ) : 1359 (M+H) Example 126: H- D- Arg- Lys ( - CO-NH- C6H5 ) - Pro- Pro- Gly- Phe- Ser- -Tic- Oic- Arg- OH MS (FAB) : 1373 (M+H) Example 127: H- D- Arg- Arg (Tos ) - Pro- Pro- Gly- Phe- Ser-D- Tic- Oic-Arg- OH MS ( FAB ) : 1436 (M+H) Example 128: H- Lys- Lys (Nicotinoyl ) - Pro- Pro- Gly- Phe- Ser-D-Tic- Oic- Arg- OH MS (FAB) : 1331 (M+H) Example 129: H- Lys- Lys ( - CO- H- C6H5 ) -Pro- Pro- Gly- Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1345 (M+H) Example 130: H-Lys-Arg(Tos ) -Pro-Pro- Gly-Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1408 (M+H) Example 131: H-D-Arg-Lys (Nicotinoyl ) -Pro-Hyp- Gly-Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1375 (M+H) Example 132: H-D- Arg- Lys ( - CO-NH- C6H5 ) -Pro-Hyp- Gly- Phe- Ser-D-Tic- Oic- Arg-OH MS { FAB ) : 1389 (M+H) Example 133: H-D-Arg-Arg (Tos ) -Pro-Hyp- Gly-Phe-Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1452 (M+H) Example 134: H- Lys- Lys (Nicotinoyl ) - Pro-Hyp- Gly- Phe- Ser- D- ic- Oic-Arg- OH MS (FAB) : 1347 (M+H) Example 135: H- Lys- Lys (-CO-NH-C6H5)- Pro-Hyp- Gly- Phe- Ser- D-Tic- Oic- Arg- OH MS ( FAB ) : 1361 (M+H) Example 136: H- Lys- Arg ( Tos ) - Pro-Hyp- Gly- Phe- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1424 (M+H) Example 137: H-D-Arg- Orn (Nicot noyl ) -Pro- Pro- Gly- Thia- Ser-D-Tic-Oic- Arg- OH MS (FAB) : 1351 (M+H) Example 138: H-D-Arg- Orn (-CO-NH- C&H5 ) -Pro- Pro-Gly-Thia- Ser-D-Tic- Oic-Arg-OH MS (FAB) : 1428 (M+H) Example 139: H-Lys- Orn (Nicotinoyl ) - ro- Pro- Gly-Thia- Ser- -Tic- Oic-Arg- OH MS (FAB) : 1323 (M+H) Example 140: H- Lys- Orn ( - CO-NH- C&H5 ) - Pro- Pro- Gly-Thia- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1337 (M+H) Example 141: H-D-Arg- Orn (Nicotinoyl) -Pro-Hyp- Gly- Thia- Ser-D-Tic- Oic- Arg-OH MS ( FAB ) : 1367 (M+H) - - Example 142: H-D- Arg- Orn (- CO- H-C&H5)- Pro-Hyp- Gly- hia- Ser-D- Tic- Oic- Arg- OH MS (FAB ) : 1381 (M+H) Example 143: H- Lys- Or (Nicotinoyl ) - Pro- Hyp- Gly-Thia- Ser-D- Tic- Oic- Arg- OH MS (FAB) : 1339 (M+H) Example 144: H- Lys- Orn( - CO- H- C6H5 ) - Pro-Hyp- Gly- Thia- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1353 (M+H) Example 145: H-D- Arg- Orn(Nicot noyl) -Pro-Pro-Gly-Phe- Ser-D-Tic- Oic-Arg- OH MS (FAB) : 1345 (M+H) Example 146: H-D- Arg- Orn( - CO-NH-C6H5) - Pro-Pro- Gly- Phe- Ser-D- Tic- Oic-Arg- OH MS (FAB) : 1359 (M+H) Example 147: H- Lys- Orn (Nicotinoyl ) -Pro- Pro- Gly-Phe- Ser-D-Tic- Oic- Arg- OH MS ( FAB ) : 1317 (M+H) Example 148: H- Lys-Orn(-CO-NH-C6H5)-Pro-Pro-Gly-Phe-Ser-D-Tic-Oic-Arg- OH MS ( FAB ) : 1331 (M+H) Example 149: H-D- Arg- Orn(Nicotinoyl )- Pro-Hyp- Gly-Phe- Ser-D-Tic-Oic- Arg-OH MS ( FAB ) : 1361 (M+H) Example 150: H- D- Arg- Orn (CO-NH- C6H5)- Pro-Hyp- Gly-Phe- Ser-D- Tic- Oic- Arg- OH MS ( FAB ) : 1375 (M+H) Example 151: H-Lys-0m(Nicotinoyl)-Pro-Hyp-Gly-Phe-Ser-D-Tic-0ic-Arg-0H MS ( FAB ) : 1333 (M+H) Example 152: H- Lys- Orn ( - CO-NH- C6H5 ) -Pro-Hyp- Gly-Phe- Ser-D-Tic- Oic- Arg- OH MS (FAB) : 1347 (M+H) Example 153: H- Lys-Lys- ro-Pro- Gly-Thia- Ser- (D) -Tic-Aoc-Arg- OH MS (FAB) : 1218 (M+H) Example 154: H- Lys- Lys- Pro-Hyp- Gly-Thia- Ser- (D) -Tic-Aoc- Arg- OH MS (FAB) : 1234 (M+H) Example 155: H- Lys- Lys- Hyp-Pro- Gly- Thia- Ser- (D)- Tic-Aoc-Arg- OH MS (FAB) : 1234 (M+H) Example 156: H- Lys- Lys- Pro- Pro- Gly-Phe- Ser- (D) -Tic-Aoc-Arg- OH MS (FAB) : 1212 (M+H) Example 157: H- Lys- Lys- Pro-Hyp- Gly- Phe- Ser- (D) -Tic-Aoc-Arg- OH MS (FAB) : 1228 (M+H) Example 158: H- Lys- Lys- Pro- Pro-Gly- Thia- Ser- (D ) - Tic- Oic-Arg- OH MS (FAB) : 1232 (M+H) Example 159: H- Lys- Lys-Pro-Hyp- Gly-Thia- Ser- (D) -Tic- Oic-Arg- OH MS (FAB) : 1248 (M+H) Example 160: H- Lys- Lys-Hyp- Pro- Gly-Thia- Ser- (D) - Tic- Oic-Arg-OH MS (FAB) : 1226 (M+H) Example 161: H-Lys- Lys- Pro-Hyp-Gly-Phe- Ser- (D ) -Tic-Oic- Arg-OH MS (FAB) : 1242 (M+H) The Examples 162-164 were prepared analogously to Example 32 using the resin having the structure described in EP-A 322,348.
Example 162: H-D-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-NH2 MS (FAB) : 1283 (M+H) Example 163: H-D-Arg-A g-Hyp-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-NH2 MS (FAB): 1283 (M+H) Example 164: H-D-Arg-Arg-Pro-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg- MS(FAB): 1267 (M+H) .Example 165 H-D-Arg-Arg-Pro-Pro-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH MS (FAB): 1267 (M + H) Example 166 H-D-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH MS (FAB): 1284 (M + H) Example 167 H-D-Arg-Lys(Z)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH MS (FAB): 1390.7 (M + H) Example 168 H-D-Arg-Lys-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH MS(FAB): 1256.7 (M + H) Example 169 H-D-Arg-Ser(Rha)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg-OH MS (FAB): 1361 (M + H) Example 170 H-D-Arg-Arg-Pro-Pro-Gly-Phe-Ser-D-Tic-Aoc-D-Ser(Rha)-OH MS(FAB): 1345 (M + H) Example 171 H-D-Arg-Arg(Tos)-Pro-Hyp-Gly-Phe-Ser-D-Tic-Aoc-Arg(Mtr)-OH MS(FAB): 1650.7 (M + H) - 43 A - Example 172 H-D-Arg-Arg-Hyp-Pro-Gly-Thia-Ser-D-Tic-D-Aoc-Arg-OH MS(FAB): 1290 (M + H) [Example 173 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-D-Oic-Arg-OH MS(FAB): 1304.7 (M + H) {Example 174 H-D-Arg-Arg-APro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS (FAB): 1302.7 (M + H) Example 175 H-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS(FAB): 1304.7 (M + H) Example 176 4-Hydroxyphenylpropionyl-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS(FAB): 1452.7 (M + H) Example 177 H-D-Arg-D-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS (FAB): 1304.7 (M + H) Example 178 H-D-Arg-Arg-D-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS (FAB): 1304.6 (M + H) Example 179 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-D-Arg-OH MS (FAB): 1304.9 (M + H) - 43 B - [Example 180 H-D-Arg-Arg-Pro-Hyp-Gly-D-Thia-Ser-D-Tic-Oic-Arg-OH MS(FAB): 1304.8 (M + H) {Example 181 H-D-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS (FAB): 1148 (M + H) Example 182 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-OH MS (FAB): 1147 (M + H) Example 183 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-D-Ser-D-Tic-Oic-Arg-OH MS (FAB): 1304.7 (M + H) Example 184 Ac-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS (FAB): 1346.9 (M + H) Example 185 H-D-Arg-Arg(Mtr)-Hyp-Pro-Gly-Thia-Ser-D-Tic-Pro-Phe-OH MS(FAB): 1454.9 (M + H) Example 186 H-D-Arg-Arg-Hyp-Pro-Gly-Thia-Gly-D-Tic-D,L-Oic-Arg-OH MS(FAB): 1274 (M + H) Example 187 H-D-Arg-Arg-Hyp-Pro-Gly-Thia-B-Ala-D-Tic-Aoc-Arg-OH MS (FAB): 1354.6 (M + H) - A3 G - Example 188 H-D-Arg-Pro-Hyp-Gly-Phe-Ser-D-Tic-Oic-Arg-OH MS (FAB): 1142.5 (M + H) Example 189 (4-Benzoyl)phenoxyacetyl-D-Arg-Arg-Pro-Hyp-Gly-T ia-Ser-D-Tic-Oic-Arg-OH MS(FAB): 1542.6 (M + H) Example 190 H-((4-Benzoyl)benzyol)-Lys-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-Arg-OH MS(FAB): 1640.9 (M + H) Example 191 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-Cys-D-Tic-Oic-Arg-OH MS(FAB): 1320.7 (M + H) Example 192 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-(3aR,7aS)Oic-Arg-OH MS (FAB): 1304.7 (M + H) Example 193 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-(3aS,7aR)Oic-Arg-OH MS(FAB): 1304.7 (M + H) Example 194 H-D-Arg-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-NH2 MS(FAB): 1147.6 (M + H) - A3 D - Example 195 H-Arg-Pro-Hyp-Gly-Thia-Ser-D-Tic-Oic-OH The peptide of Example 195 was prepared analogously to Example 1, however, the peptide was split off from the resin as follows: The peptide resin is treated with a mixture of m-cresole and dichloromethane (1 :2) (about 2ml/g resin) for 10 min to swell the resin. Then trifluoroacetic acid (about 10 ml/g resin) and with stirring bromotrimethylsilane (about 0.8 ml/g resin) is added. After 1.5 h reaction time the mixture is filtered through a sintered glass funnel into icecold methyl-tert.butylether. The precipitated crude peptide is collected by filtration, washed with methyl-tert.butylether and then dried. The crude peptide is dissolved in water, the aqueous solution is extracted with ethylacetate and then treated with ion exchange resin (IRA 93, acetate form). The ion exchanger is removed by filtration, washed with water and the aqueous solution is lyophilized. The crude peptide now obtained as acetate is purified by chromatography on ®Sephadex LH 20 with 10 % aqueous acetic acid. The fractions which contain the pure peptide are combined and lyophilized.
MS (FAB): 992.6 (M + H). - 43 E - Example No. •Cso [MJ 1 4.6 x 10 3 2.1 x 10* 4 1.2 X 10* 5 2.4 x 105 6 2.5 x 10-7 7 3.7 x 10* 8 1.9 x 107 9 4.6 x 10* 13 6.0 x 10* 19 3.4 x 10* 23 4.8 X 10*7 24 1.1 x 10* 27 2.5 x 10* 29 3.7 x 107 38 6.0 x 10* 39 1.7 x 10* 44 3.9 X 107 45 4.8 x 10"7 47 1.7 x ισ7 48 9.5 x 10* 54 8.9 x 10* 56 8.0 X 107 57 6.2 x 10* 58 2.6 X 10'5 59 5.4 x 10* 60 4.2 x 10* 64 6.8 x 10* 67 6.4 x 10* 72 1.8 x 10* 73 3.0 x 10* 74 4.8 x 10* 75 3.0 x 10* 76 3.2 x 107 77 7.0 x 10* 78 2.5 x 107 ' 79 3.5 x 10* IC-so [ ] 194

Claims (7)

- 44 - HOE 88/F 328K Patent claims : A peptide of the formula I A-B-C-E-F-K- (D)-Tic-G-M-F'- I (I) , in which A a1) denotes hydrogen, (C^Ce )-alkyl, (Ci-Ca) -alkanoyl , (Ci-CgJ-alkoxycarbonyl or (C^-Cu) -alkylsulfonyl, in which in each case 1, 2 or 3 hydrogen atoms are optionally replaced by 1, 2 or 3 identical or different radicals from the series comprising carboxyl, amino, (Ci-CJ-alkyl, ( Ci-C* ) -alkylamino, hydroxy1 , (Ci-C -alkoxy, halogen, di- ( Ci-C* ) -alkylamino , carbamoyl, sulfamoyl, ( Ci-C^ ) -alkoxycarbonyl , (C6-C12)-aryl and (C8-C^-aryl-^-CsJ-alkyl, or in which in each case 1 hydrogen atom is optionally replaced by a radical from the series comprising (C3-C8 ) -eyeloalky1 , ( C-!-C^ ) -alkylsulfonyl , (Cj-C -alkylsulfinyl, (C6-C12) -aryl- ( Ct-CJ -alkylsulfonyl , (C6-C12) -aryl- ( Cj-C,, ) -alkylsulfinyl , (C6-C12) -aryloxy, (C3-C9)-heteroaryl and ( C3-C9) -heteroaryloxy - 45 - and
1. Or 2 hydrogen atoms are replaced by 1 or 2 identical or different radicals from the series comprising carboxyl , amino, ( Ci-C* ) -alkylamino , hydroxyl , (Cx-C*)-alkoxy, halogen, di- ( Ci-C* ) -alkylamino , carbamoyl , sulfamoyl, ( Ci-C*) -alkoxycarbonyl , (Ce-C^J-aryl and ( C5-C12) -aryl- (C.-C,) -alkyl , a2) denotes (C3-C8)-cycloalkyl, carbamoyl, which may be optionally substituted on the nitrogen by (Ci-Ce) -alkyl or (C6-Cu)-aryl, (C6-C12)-aryl, (C7-C18) -aryloyl, (Cg-C^) -arylsulfonyl or (C3-C9) -heteroaryl or (C3-C9) -heteroaryloyl, where in the radicals defined under at) and a2) in each case heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl is optionally substituted by 1, 2, 3 or 4 identical ©r different radicals from the series comprising carboxyl, amino, nitro , ( Ci-C* ) -alkylamino , hydroxyl , (C!-CJ -alkyl, (Ci-CJ-alkoxy, halogen, cyano, di- ( Ci-C^ ) -alkylamino, carbamoyl , sulfamoyl and (Ci-C -alkoxycarbonyl, or - 46 - a3) denotes a radical of the formula II R1 - N - CH - C - 2 R3 8 (") R1 is defined as A under ax) or a2) , R2 denotes hydrogen or methyl, R3 denotes hydrogen or (Ci-CgJ-alkyl, preferably (Ci-C*) -alkyl, which is optionally monosubstituted by amino, substituted amino, hydroxyl , carboxyl , carbamoyl , guanidino, substituted guanidino, ureido, mereapto, methylmercap o , phenyl , 4-chlorophenyl , 4-fluorophenyl , 4-nitrophenyl , 4-methoxyphenyl , 4-hydroxyphenyl , phthalimido, 4-imidazolyl, 3-indolyl, 2-thienyl, 3-thienyl,
2. -pyridyl, 3-pyridyl or cyclohexyl, where substituted amino stands for a compound -NH-A- and substituted guanidino stands for a compound -NH-C (NH) -NH-A, in which A is defined as under ax) or a2); B stands for a basic amino acid in the L- or D-con- figuration, which may be substituted in the side chain; - 47 - C stands for a compound of the formula Ilia or Illb G'-G'-Gly G 1 - H- (CH2)n-CO (Ilia) (Illb) in which in which R* and R5 together with the atoms carrying them form a heterocyclic mono-, bi- or tricyclic ring system having 2 to 15 carbon atoms, and n is 2 to 8; E stands for the radical of an aromatic amino acid; F independently of one another denotes the radical of a neutral, acidic or basic, aliphatic or aromatic amino acid which may be substituted in the side chain, or stands for a direct bond; (D)-Tic denotes G is as defined above for G' or denotes a direct bond; F' is as defined for F, denotes a radical -NH-(CH2)n-, with n = 2 to 8, or, if G does not denote a direct bond, can stand for a direct bond, and I is -OH, -NH2 or -NHC2H5, K denotes the radical -NH- (CH2)x-CO- with x = 1-4 or stands for a direct bond, and M is as defined for F, and their physiologically tolerable salts. A peptide of the formula I as claimed in claim 1, in which B denotes Arg, Lys, Orn, 2 , 4-diaminobutyroyl or an L- homoarginine radical, where in each case the amino or guanidino group of the side chain may be sub- - 48 - 51298/2 stituted by A as described under ax) or a2) in claim 1; E stands for the radical of an aromatic amino acid in the L- or D-configuration, which contains 6 to 14 carbon atoms in the aryl moiety as ring members, selected from phenylalanine which is optionally substituted by halogen in the 2-, 3- or 4-position, tyrosine, 0- methyltyrosine, 2-thienylalanine, 2-pyridylalanine or naphthylalanine; F' denotes the radical of a basic amino acid in the L- or D-configuration, such as Arg or Lys, where the guanidino group or amino group of the side chain may be replaced by A as described under ax) or a2) in claim 1, or denotes a radical -NH-(CH2)n - with n = 2 to 8 and K stands for the radical -NH- (CH2)X-C0- with x = 2-4 or denotes a direct bond. A peptide of the formula I as claimed in claim 1 and/or 2 in which B denotes Arg, Orn or Lys, where the guanidino group or the amino group of the side chain is unsubsti- tuted or may be substituted by (C^-Ca) -alkanoyl, (C7- C13)-aryloyl, (C3-C9)-heteroaryloyl, (Ci-Ce) -alkylsul- fonyl or (C6-C12)-arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted, as described under a2) , with 1, 2, 3 or 4 identical or different radicals . E denotes phenylalanine, 2-chlorophenylalanine,
3. -chlorophenylalanine , 4-chlorophenylalanine , 2-f luorophenylalanine , 3-fluorophenylalanine ,
4. -fluorophenylalanine, tyrosine, O-methyltyrosine or β-( 2-thienyl) alanine; - 49 - K stands for a direct bond and M stands for a direct bond. A peptide of the formula I as claimed in one or more of claims 1 to 3 in which A denotes hydrogen, (D)- or (L)-H-Arg, (D)- or (L)-H- Lys or (D)- or (L)-H-Orn; B denotes Arg# Orn or Lys, where the guanidino group or the amino group of the side chain may be substituted by hydrogen, (Ci-CgJ-alkanoyl, (C7-C13)- aryloyl, (C3-C9) -heteroaryloyl, (Ci-Ce) -alkylsulfonyl or (C6-C12) -arylsulfonyl, where the aryl, heteroaryl, aryloyl, arylsulfonyl and heteroaryloyl radicals may optionally be substituted with 1, 2, 3 or 4 identical or different radicals from the series comprising methyl, methoxy and halogen. C denotes Pro-Pro-Gly, Hyp-Pro-Gly or Pro-Hyp-Gly E denotes Phe or Thia F denotes Ser, Hser, Lys, Leu, Val, Nle, lie or Thr K stands for a direct bond M stands for a direct bond G stands for the radical of a heterocyclic ring system of the formula IV, where the radicals of the hetero- cycles pyrrolidine (A); piperidine (B); tetrahydro- isoquinoline (C) ; cis- and trans-decahydroisoquino- line (D) ; cis-endo-octahydroindole (E) , cis-exo- octahydroindole (E), trans-octahydroindole (E), cis- endo-, cis-exo-, trans-octahydrocyclopentano[b]pyr- role, (F) or hydroxyproline (V) are preferred. - 50 - SEE298/2 F denote Arg and I stands for OH.
5. The preparation of a peptide of the formula I as claimed in one or more of claims 1 to 4, which comprises a) reacting a fragment having a C-terminal free car- boxyl group or its activated derivative with an appropriate fragment having an N-terminal free amino group or b) synthesizing the peptide stepwise, optionally splitting off one or more protective groups temporarily introduced for the protection of other functions in the compound obtained according to (a) or (b) and optionally converting the compounds of the formula I thus obtained into their physiologically tolerable salt.
6. Use of a peptide of the formula I as claimed in one or more of claims 1 to 4 in the preparation of a medicament/ substantially as described in the specification.
7. Use of a peptide of the formula I as claimed in one or more of claims 1 to 4 in the preparation of a medicament for the treatment of pathological states which are mediated, caused or supported by bradykinin and bradykinin-related peptides, substantially described in the specification. A pharmaceutical agent containing a peptide of the formula I as claimed in one or more of claims 1 to 4.
IL9129889A 1988-11-24 1989-08-11 Peptides having bradykinin antagonist action, their preparation and use IL91298A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3839581 1988-11-24
DE3916291 1989-05-19
DE3918225 1989-06-03

Publications (2)

Publication Number Publication Date
IL91298A0 IL91298A0 (en) 1990-03-19
IL91298A true IL91298A (en) 1994-05-30

Family

ID=27198531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9129889A IL91298A (en) 1988-11-24 1989-08-11 Peptides having bradykinin antagonist action, their preparation and use

Country Status (26)

Country Link
EP (1) EP0370453B1 (en)
JP (1) JPH07121956B2 (en)
KR (1) KR0139632B1 (en)
CN (1) CN1035006C (en)
AT (1) ATE107318T1 (en)
AU (1) AU612054B2 (en)
CA (1) CA1340667C (en)
CY (2) CY2028A (en)
CZ (1) CZ282384B6 (en)
DE (3) DE58907889D1 (en)
DK (1) DK175344B1 (en)
ES (1) ES2057071T3 (en)
FI (1) FI94353C (en)
HK (1) HK1006716A1 (en)
HU (2) HU210566B (en)
IE (1) IE63490B1 (en)
IL (1) IL91298A (en)
LU (1) LU91499I2 (en)
LV (1) LV10720B (en)
MX (1) MX9203277A (en)
NL (1) NL300359I2 (en)
NO (2) NO177597C (en)
NZ (1) NZ230244A (en)
PH (1) PH31009A (en)
PT (1) PT91692B (en)
SK (1) SK279315B6 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648333A (en) * 1988-11-24 1997-07-15 Hoechst Aktiengesellschaft Peptides having bradykinin antagonist action
DE4013270A1 (en) * 1990-04-26 1991-10-31 Hoechst Ag PEPTIDES WITH BRADYKININ ANTAGONISTIC EFFECT
EP0502987B1 (en) * 1989-12-08 1994-08-31 Trustees Of Boston University Acylated bradykinin antagonists and uses therefor
MX9100717A (en) * 1990-08-24 1992-04-01 Syntex Inc BRADIQUININE ANTAGONISTS
US5416191A (en) * 1991-04-01 1995-05-16 Cortech, Inc. Bradykinin antagonists
US5843900A (en) * 1991-04-01 1998-12-01 Cortech, Inc. Bradykinin antagonists
DE69231918D1 (en) * 1991-04-19 2001-08-09 Scios Nova Inc PEPTIDANTAGONISTS OF BRADYKININ
US6770741B1 (en) 1991-04-19 2004-08-03 Scios Inc. Bradykinin antagonist peptides
ATE169823T1 (en) * 1991-04-19 1998-09-15 Scios Nova Inc BRADYKININ TYPICAL PEPTIDES
HUT63060A (en) * 1991-08-22 1993-07-28 Hoechst Ag Process for producing pharmaceutical compositions locally applicable on nose and eye, comprising bradykinin antagonists
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
WO1993011789A1 (en) * 1991-12-12 1993-06-24 Scios Nova Inc. Modified position (7) bradykinin antagonist peptides
TW199863B (en) * 1991-12-21 1993-02-11 Hoechst Ag
WO1993017701A1 (en) * 1992-03-12 1993-09-16 The Administrators Of The Tulane Educational Fund Endothelin receptor-binding peptides
TW258739B (en) * 1992-04-04 1995-10-01 Hoechst Ag
FR2692581B1 (en) * 1992-06-18 1994-08-19 Adir New peptide derivatives with bradykinin antagonist activity, their preparation process and the pharmaceutical compositions containing them.
US5521158A (en) * 1992-10-08 1996-05-28 Scios Nova Inc. Pseudopeptide bradykinin receptor antagonists
US5610142A (en) * 1992-10-08 1997-03-11 Scios Inc. Bradykinin antagonist pseudopeptide derivatives of substituted 4-keto-1,3,8-triazaspiro[4.5]decan-3-alkanoic acids
US5686565A (en) * 1992-10-08 1997-11-11 Scios Inc. Bradykinin antagonist pseudopeptide derivatives of aminoalkanoic acids and related olefins
US5541286A (en) * 1992-10-08 1996-07-30 Scios Nova Inc. Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids
IL107400A0 (en) * 1992-11-10 1994-01-25 Cortech Inc Bradykinin antagonists
WO1994019372A1 (en) * 1993-02-17 1994-09-01 Scios Nova Inc. Cyclic bradykinin antagonist peptides
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
DE4345062A1 (en) * 1993-12-31 1995-07-13 Hoechst Ag Use of bradykinin antagonists for the manufacture of medicaments for the treatment of viral diseases
ATE280777T1 (en) * 1994-03-09 2004-11-15 Cortech Inc BRADYKININ ANTAGONIST PEPTIDES WITH N-SUBSTITUTED GLYCINES
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
EP0832106A2 (en) * 1995-06-05 1998-04-01 Cortech, Inc. Compounds having bradykinin antagonistic activity and mu-opioid agonistic activity
US5770687A (en) * 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US6051554A (en) * 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
FR2737408B1 (en) * 1995-07-31 1997-09-05 Oreal USE OF A BRADYKININE ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED
US5849863A (en) * 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
US5834431A (en) * 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
FR2739553B1 (en) 1995-10-06 1998-01-02 Oreal USE OF BRADYKININE ANTAGONISTS TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THE HAIR LOSS
US6841533B1 (en) 1995-12-07 2005-01-11 Peptor Limited Conformationally constrained backbone cyclized interleukin-6 antagonists
DE19612067A1 (en) * 1996-03-27 1997-10-02 Hoechst Ag Use of bradykinin antagonists for the manufacture of medicaments for the treatment of chronic fibrogenetic liver diseases and acute liver diseases
US6355613B1 (en) 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
DE19642289A1 (en) * 1996-10-14 1998-04-16 Hoechst Ag Use of bradykinin antagonists for the manufacture of medicaments for the treatment and prevention of Alzheimer's disease
DE10304994A1 (en) * 2003-02-07 2004-09-02 Aventis Pharma Deutschland Gmbh The use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis
CN102532267B (en) * 2012-02-09 2014-06-18 深圳翰宇药业股份有限公司 Method for preparing icatibant
CN104043101B (en) * 2014-05-23 2016-04-20 杭州阿德莱诺泰制药技术有限公司 A kind of icatibant composition for injection and preparation method thereof and preparation
KR102099509B1 (en) 2018-07-27 2020-04-09 강경순 Supports for fruit trees
CN111944016B (en) * 2020-08-25 2022-04-29 台州吉诺生物科技有限公司 Preparation method of icatibant acetate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3044236A1 (en) * 1980-11-25 1982-06-16 Hoechst Ag, 6000 Frankfurt AMINO ACID DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
FR2487829A2 (en) * 1979-12-07 1982-02-05 Science Union & Cie NOVEL SUBSTITUTED IMINO ACIDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
DE3227055A1 (en) * 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt NEW DERIVATIVES OF 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF, AND 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID AS ANSWER FOR THEIR PRODUCTION
FR2575753B1 (en) * 1985-01-07 1987-02-20 Adir NOVEL PEPTIDE DERIVATIVES WITH NITROGEN POLYCYCLIC STRUCTURE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US4693993A (en) * 1985-06-13 1987-09-15 Stewart John M Bradykinin antagonist peptides

Also Published As

Publication number Publication date
HK1006716A1 (en) 1999-03-12
FI94353C (en) 1995-08-25
IE63490B1 (en) 1995-05-03
SK490689A3 (en) 1998-09-09
DK175344B1 (en) 2004-08-30
NO177597C (en) 1995-10-18
NL300359I2 (en) 2009-02-02
ATE107318T1 (en) 1994-07-15
AU612054B2 (en) 1991-06-27
CN1035006C (en) 1997-05-28
DE122008000066I2 (en) 2009-11-05
EP0370453B1 (en) 1994-06-15
KR0139632B1 (en) 1998-07-01
CA1340667C (en) 1999-07-20
FI893738A (en) 1990-05-25
LV10720A (en) 1995-06-20
CZ282384B6 (en) 1997-07-16
CY2008022I1 (en) 2009-11-04
LU91499I2 (en) 2009-01-19
HUT52527A (en) 1990-07-28
NO177597B (en) 1995-07-10
FI94353B (en) 1995-05-15
DK384089D0 (en) 1989-08-04
KR900007870A (en) 1990-06-02
IE892522L (en) 1990-05-24
EP0370453A3 (en) 1991-12-04
MX9203277A (en) 1992-07-01
CY2008022I2 (en) 2009-11-04
NO893193D0 (en) 1989-08-08
DE3938751A1 (en) 1990-05-31
JPH07121956B2 (en) 1995-12-25
NL300359I1 (en) 2008-11-03
FI893738A0 (en) 1989-08-08
ES2057071T3 (en) 1994-10-16
PH31009A (en) 1997-12-23
CY2028A (en) 1998-02-20
AU3943189A (en) 1990-05-31
LV10720B (en) 1996-02-20
NO893193L (en) 1990-05-25
DK384089A (en) 1990-05-25
HU210566B (en) 1995-05-29
NO2008016I2 (en) 2012-10-01
DE122008000066I1 (en) 2009-05-20
PT91692B (en) 1995-05-31
DE58907889D1 (en) 1994-07-21
EP0370453A2 (en) 1990-05-30
CZ490689A3 (en) 1997-03-12
NO2008016I1 (en) 2008-11-17
JPH02184697A (en) 1990-07-19
PT91692A (en) 1990-03-30
HU210712A9 (en) 1995-06-28
CN1042918A (en) 1990-06-13
IL91298A0 (en) 1990-03-19
NZ230244A (en) 1992-06-25
SK279315B6 (en) 1998-09-09

Similar Documents

Publication Publication Date Title
CA1340667C (en) Peptides having bradykinin antagonist action
CA2023194C (en) Peptides having bradykinin antagonist action
US5648333A (en) Peptides having bradykinin antagonist action
US5597803A (en) Bradykinin peptides with modifications at the N terminus
JP2552402B2 (en) Bradykinin antagonistic peptide
CN1034416Y (en) Preparation method of peptide with bradykinin antagonism
RU2083586C1 (en) Peptides and their physiologically acceptable salts
LT3872B (en) Novel peptides and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed